Posted on July 16, 2019 by Sitemaster
A lot of people are hopeful that treatment with a new form of targeted nuclear radiation therapy — lutetium-177 PSMA 617 (177Lu PSMA) — will be able to significantly extend survival of men with metastatic, castration-resistant prostate cancer (mCRPC) … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, NOX66, PSMA | 1 Comment »
Posted on June 9, 2019 by Sitemaster
At the end of May, just prior to the annual meeting of ASCO, the US Food and Drug Administration (FDA) granted fast track designation to an investigational agent called ARV-110 for treatment of metastatic, castration-resistant prostate cancer (mCRPC). … -READ MORE …
Filed under: Drugs in development | Tagged: ARV-110, castration-resistant, fast, FDA, mCRPC, metastatic, track | Leave a comment »
Posted on May 18, 2019 by Sitemaster
We have noted several times in the past that, at least to date, compared to the results shown by the PD-1 and PD-L1 checkpoint inhibitors in the treatment of cancers like lung cancer, kidney cancer, and melanoma, there has been little evidence of the value of these agents in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab. Keytruda, HSPC, mCRPC, nivolumab, Opdivo, PD-1, PD-L1, pembrolizumab, Tecentriq | 7 Comments »
Posted on March 29, 2019 by Sitemaster
Unfortunately we don’t always hear about some interesting clinical trials as early as we would like to. The following is a case in point. … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, castration-resistant, first line, inhibitor, mCRPC, metastatic, olaparib, PARP | 4 Comments »
Posted on March 1, 2019 by Sitemaster
Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: inhibitor, mCRPC, niraparib, olaparib, PARP, Phase III, rucaparib, talazoparib | 5 Comments »
Posted on February 26, 2019 by Sitemaster
We know that both abiraterone acetate (Zytiga) and enzalutamide (Xtandi) can be used to extend the survival of men with mCRPC who have already been treated with docetaxel + prednisone. However, … READ MORE …
Filed under: Uncategorized | Tagged: castration-resistant, CHEIRON, combination, docetaxel, enzalutamide, mCRPC, metastatic, trial | Leave a comment »
Posted on December 27, 2018 by Sitemaster
A new paper in the Journal of Clinical Oncology has just reported that the overall survival (OS) of black and white men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) seems to be near to identical after treatment with docetaxel or a docetaxel-containing regimen. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: black, castration-resistant, docetaxel, mCRPC, metastatic, race, survival, white | Leave a comment »
